Equifax enters May with a bruising April earnings reaction still fresh — and its CEO selling into the weakness.
Mark Begor filed four sell transactions on April 24, three days after the stock dropped nearly 10% on Q1 results. Combined, the trades totalled roughly $6.5M at prices between $171.57 and $174.32. The sells came just as short sellers were stepping up their own pressure. ORTEX estimates short interest has risen 13% over the past week and 14% over the past month, reaching 4.5% of free float — still a moderate level in absolute terms, but the rate of accumulation stands out. The next earnings event arrives May 7, and the stock closed Wednesday at $172.56, down 3.4% on the week.
The positioning picture is building but not yet extreme. Short interest at 4.5% of free float puts EFX in the middle of its recent range, and the borrow market remains loose. Cost to borrow has crept up — now at 0.53%, about 28% higher than a month ago — but in absolute terms it is barely above zero. Availability is not under meaningful stress. The ORTEX short score of 39 ranks in the 37th percentile of the universe, reinforcing the read that bears are accumulating rather than piling in. The options market adds little to the bear thesis: the put/call ratio of 1.06 is virtually identical to its 20-day average of 1.06, with a z-score close to zero — no unusual skew in either direction.
The Street is still broadly constructive, but April dented conviction. Multiple analysts trimmed price targets in the days following the Q1 miss. UBS cut its target from $245 to $220 while holding Buy. Wells Fargo and Baird both lowered targets — to $230 and $245 respectively — while keeping positive ratings. Needham stood pat at $265. The net effect: the consensus mean target sits near $228, implying roughly 32% upside from current levels. That gap looks generous given the near-term macro headwinds the bear case names directly — declining mortgage origination volumes, slowing international revenue growth, and continued sensitivity to lending conditions in Canada and the UK. Goldman Sachs, on the sidelines at Neutral with a $208 target, has the most sober read on near-term fundamentals. EPS momentum scores of 62 and 63 (30- and 90-day) suggest estimate revisions remain mildly positive — the earnings trend hasn't broken, but the reaction to the April print shows the market has little patience for any shortfall. The analyst recommendation divergence factor scores in the 94th percentile, meaning the gap between the Street's stated ratings and actual performance is unusually wide right now.
The most recent earnings history sharpens the stakes for May 7. The April 21 print delivered a 10% single-day drop and a 13.5% five-day decline — the sharpest post-earnings move in recent data. The prior event, in mid-April 2026 (Q4 reporting cycle), posted a modest 2.1% gain before fading 4.2% over the following week. Two consecutive prints with negative five-day outcomes frame the upcoming release as a binary moment. Closest peer TRU — which carries an 84% correlation to EFX — fell 9.5% on the week, a sharper move than EFX's own 3.4% decline, suggesting the credit-data complex is under broad pressure rather than EFX-specific stress.
The combination to watch into May 7 is whether short interest continues its current accumulation pace — and whether insider selling by the CEO proves a one-off or the start of a sustained pattern.
See the live data behind this article on ORTEX.
Open EFX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
